Literature DB >> 18379876

Akt1/protein kinase B alpha is involved in gastric cancer progression and cell proliferation.

Zheyi Han1, Kaichun Wu, Huiqin Shen, Chunying Li, Shuang Han, Liu Hong, Yongquan Shi, Na Liu, Changcun Guo, Yan Xue, Taidong Qiao, Daiming Fan.   

Abstract

Akt (also known as protein kinase B, PKB) is involved in a variety of biological processes, for example cell development, proliferation, and angiogenesis. Clinical studies in support of the idea that increased activity of Akt could contribute directly to gastric carcinogenesis are rare, however. In this study we discovered that phospho-Akt1 was overexpressed in human gastric cancers and its levels correlated with tumor differentiation and pTNM. Akt1 activation promoted cell survival, because the phosphatidylinositol 3-kinase(PI3K) inhibitor LY294002 inhibited Akt1 phosphorylation and inhibited cell growth, especially in cells with active Akt1. Dominant negative Akt inhibited proliferation of gastric cancer cells and induced G1 cell-cycle arrest whereas constitutively active Akt increased cell proliferation. We have therefore identified Akt1 as an active kinase that contributes to gastric cancer progression and promotes proliferation of gastric cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18379876     DOI: 10.1007/s10620-007-9824-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  30 in total

1.  Oncogenic transformation induced by membrane-targeted Akt2 and Akt3.

Authors:  I Mende; S Malstrom; P N Tsichlis; P K Vogt; M Aoki
Journal:  Oncogene       Date:  2001-07-19       Impact factor: 9.867

Review 2.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

3.  AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival.

Authors:  Ying Li; Donald Dowbenko; Laurence A Lasky
Journal:  J Biol Chem       Date:  2001-12-27       Impact factor: 5.157

4.  Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique.

Authors:  J Ren; Z Chen; S J Juan; X Y Yong; B R Pan; D M Fan
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

5.  Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation.

Authors:  J Okano; I Gaslightwala; M J Birnbaum; A K Rustgi; H Nakagawa
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

6.  Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.

Authors:  J Q Cheng; B Ruggeri; W M Klein; G Sonoda; D A Altomare; D K Watson; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

7.  Translocation of Akt/PKB to the nucleus of osteoblast-like MC3T3-E1 cells exposed to proliferative growth factors.

Authors:  P Borgatti; A M Martelli; A Bellacosa; R Casto; L Massari; S Capitani; L M Neri
Journal:  FEBS Lett       Date:  2000-07-14       Impact factor: 4.124

8.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.

Authors:  Incheol Shin; F Michael Yakes; Federico Rojo; Nah-Young Shin; Andrei V Bakin; Jose Baselga; Carlos L Arteaga
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

Review 9.  The epidemiology of gastric cancer.

Authors:  David M Roder
Journal:  Gastric Cancer       Date:  2002       Impact factor: 7.370

10.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.

Authors:  A Bellacosa; D de Feo; A K Godwin; D W Bell; J Q Cheng; D A Altomare; M Wan; L Dubeau; G Scambia; V Masciullo; G Ferrandina; P Benedetti Panici; S Mancuso; G Neri; J R Testa
Journal:  Int J Cancer       Date:  1995-08-22       Impact factor: 7.396

View more
  15 in total

1.  Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).

Authors:  Ramesh K Ramanathan; Shannon L McDonough; Hagen F Kennecke; Syma Iqbal; Joaquina C Baranda; Tara E Seery; Howard J Lim; Aram F Hezel; Gina M Vaccaro; Charles D Blanke
Journal:  Cancer       Date:  2015-03-30       Impact factor: 6.860

2.  PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target.

Authors:  Jiarong Li; Andrew C Karaplis; Dao C Huang; Peter M Siegel; Anne Camirand; Xian Fang Yang; William J Muller; Richard Kremer
Journal:  J Clin Invest       Date:  2011-11-07       Impact factor: 14.808

3.  Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer.

Authors:  Sara M Johnson; Pat Gulhati; Bill A Rampy; Yimei Han; Piotr G Rychahou; Hung Q Doan; Heidi L Weiss; B Mark Evers
Journal:  J Am Coll Surg       Date:  2010-05       Impact factor: 6.113

Review 4.  The unconventional role of Akt1 in the advanced cancers and in diabetes-promoted carcinogenesis.

Authors:  Abdulrahman Alwhaibi; Arti Verma; Mir S Adil; Payaningal R Somanath
Journal:  Pharmacol Res       Date:  2019-05-09       Impact factor: 7.658

5.  Integrating Network Pharmacology and Experimental Verification to Explore the Pharmacological Mechanisms of Aloin Against Gastric Cancer.

Authors:  Jia Gao; Sifu Yang; Guanqun Xie; Jieli Pan; Feiye Zhu
Journal:  Drug Des Devel Ther       Date:  2022-06-20       Impact factor: 4.319

6.  Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis.

Authors:  Piotr G Rychahou; JungHee Kang; Pat Gulhati; Hung Q Doan; L Andy Chen; Shu-Yuan Xiao; Dai H Chung; B Mark Evers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

7.  Activated Akt as an indicator of prognosis in gastric cancer.

Authors:  Caterina Cinti; Carla Vindigni; Alessandra Zamparelli; Dario La Sala; Maria Carmela Epistolato; Daniele Marrelli; Gabriele Cevenini; Piero Tosi
Journal:  Virchows Arch       Date:  2008-10-08       Impact factor: 4.064

Review 8.  Gastric cancer in the era of molecularly targeted agents: current drug development strategies.

Authors:  Hendrik-Tobias Arkenau
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-11       Impact factor: 4.553

9.  Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibody.

Authors:  Anne Camirand; Ibtihal Fadhil; Aimée-Lee Luco; Benoît Ochietti; Richard B Kremer
Journal:  Am J Cancer Res       Date:  2013-11-01       Impact factor: 6.166

10.  CRIP1 cooperates with BRCA2 to drive the nuclear enrichment of RAD51 and to facilitate homologous repair upon DNA damage induced by chemotherapy.

Authors:  Huiying Sun; Rui Zhou; Yannan Zheng; Zhaowei Wen; Dingling Zhang; Dongqiang Zeng; Jianhua Wu; Zhenhua Huang; Xiaoxiang Rong; Na Huang; Li Sun; Jianping Bin; Yulin Liao; Min Shi; Wangjun Liao
Journal:  Oncogene       Date:  2021-07-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.